T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Rivian
RIVN
|
+$18.7B |
| 2 |
Apple
AAPL
|
+$5.48B |
| 3 |
NVIDIA
NVDA
|
+$5.33B |
| 4 |
Tesla
TSLA
|
+$4.47B |
| 5 |
Microsoft
MSFT
|
+$2.15B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Visa
V
|
+$4.26B |
| 2 |
Meta Platforms (Facebook)
META
|
+$3.3B |
| 3 |
Morgan Stanley
MS
|
+$2.82B |
| 4 |
Global Payments
GPN
|
+$2.43B |
| 5 |
PayPal
PYPL
|
+$2B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 27.4% |
| 2 | Healthcare | 16.1% |
| 3 | Consumer Discretionary | 15.8% |
| 4 | Communication Services | 12.38% |
| 5 | Financials | 10.77% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
PACW
1751
DELISTED
PacWest Bancorp
PACW
| $1.82M | ﹤0.01% |
40,400
-1,144
| -3% | -$53.3K |
|
1752
Enpro
NPO
$7.25B
| $1.82M | ﹤0.01% |
16,539
-498
| -3% | -$50K |
|
1753
Simmons First National
SFNC
$3.47B
| $1.82M | ﹤0.01% |
61,417
-1,291
| -2% | -$39.2K |
|
1754
HealthEquity
HQY
$8.79B
| $1.82M | ﹤0.01% |
41,053
+5,129
| +14% | +$299K |
|
1755
Avista
AVA
$3.28B
| $1.8M | ﹤0.01% |
42,287
+1,253
| +3% | +$50.4K |
|
|
REGI
1756
DELISTED
Renewable Energy Group, Inc.
REGI
| $1.8M | ﹤0.01% |
42,333
-52,980
| -56% | -$2.71M |
|
1757
WaFd
WAFD
$2.8B
| $1.79M | ﹤0.01% |
53,641
-2,541
| -5% | -$87.7K |
|
1758
Artisan Partners
APAM
$3.01B
| $1.78M | ﹤0.01% |
37,446
+626
| +2% | +$30.1K |
|
|
WCC
1759
WESCO International
WCC
$17.6B
| $1.78M | ﹤0.01% |
13,548
-747
| -5% | -$95.5K |
|
1760
Saic
SAIC
$5.34B
| $1.78M | ﹤0.01% |
21,308
+182
| +0.9% | +$15.8K |
|
1761
Sabra Healthcare REIT
SBRA
$5.17B
| $1.78M | ﹤0.01% |
131,442
-6,090
| -4% | -$86.2K |
|
1762
TD Synnex
SNX
$20.7B
| $1.78M | ﹤0.01% |
15,549
-676
| -4% | -$73.5K |
|
1763
Varonis Systems
VRNS
$5.15B
| $1.78M | ﹤0.01% |
36,424
-1,752
| -5% | -$99.8K |
|
1764
CryoPort
CYRX
$766M
| $1.78M | ﹤0.01% |
30,009
-1,352
| -4% | -$93.6K |
|
|
VNE
1765
DELISTED
Veoneer, Inc.
VNE
| $1.76M | ﹤0.01% |
49,694
-10,850
| -18% | -$384K |
|
1766
iShares Russell 2000 Growth ETF
IWO
$15.1B
| $1.76M | ﹤0.01% |
6,013
| – | – |
|
1767
Newmark Group
NMRK
$2.76B
| $1.76M | ﹤0.01% |
94,214
+15,297
| +19% | +$244K |
|
1768
MGIC Investment
MTG
$6.35B
| $1.76M | ﹤0.01% |
122,105
-6,118
| -5% | -$92.7K |
|
1769
Pediatrix Medical
MD
$2.17B
| $1.76M | ﹤0.01% |
64,628
-3,896
| -6% | -$104K |
|
1770
Piper Sandler
PIPR
$5.45B
| $1.75M | ﹤0.01% |
39,204
-180
| -0.5% | -$7.65K |
|
|
CIM
1771
Chimera Investment
CIM
$991M
| $1.74M | ﹤0.01% |
38,494
-1,272
| -3% | -$60.1K |
|
1772
MillerKnoll
MLKN
$1.62B
| $1.73M | ﹤0.01% |
44,170
+803
| +2% | +$31.2K |
|
1773
MDU Resources
MDU
$4.35B
| $1.73M | ﹤0.01% |
147,466
-12,573
| -8% | -$142K |
|
1774
Zillow
ZG
$7.9B
| $1.72M | ﹤0.01% |
27,682
+1,051
| +4% | +$75.5K |
|
1775
WD-40
WDFC
$3.09B
| $1.72M | ﹤0.01% |
7,025
-239
| -3% | -$55.6K |
|
Similar funds
T. Rowe Price Associates's Q4 2021 Portfolio in Review
As of Q4 2021, T. Rowe Price Associates held 3,121 positions worth $1.11T, up 4.6% from $1.06T the previous quarter. Its ten largest holdings account for 28% of the portfolio.
T. Rowe Price Associates's Q4 2021 filing shows 186 new, 817 increased, 1,825 reduced and 148 closed positions. Its largest new stake was Rivian: 162,080,423 shares worth $16.1B. The largest sale was Visa, an estimated $4.26B.
By sector, the portfolio is most concentrated in Technology at 27% of assets, up from 25% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q4 2021 buy was Rivian: 162,080,423 shares worth $16.1B.
- T. Rowe Price Associates added most to Apple in Q4 2021, an estimated $5.48B increase.
- T. Rowe Price Associates's biggest Q4 2021 reduction was Visa, cutting an estimated $4.26B.
- T. Rowe Price Associates fully exited Acceleron Pharma in Q4 2021, selling an estimated $923M.
- T. Rowe Price Associates's ten largest holdings make up 28% of its $1.11T portfolio in Q4 2021.
- T. Rowe Price Associates opened 186 new positions and closed 148 in Q4 2021.
- T. Rowe Price Associates's portfolio value rose 4.6% quarter-over-quarter to $1.11T.
Based on T. Rowe Price Associates's 13F filing for Q4 2021, filed 14 Feb 2022.